Sonja Nelson
CIK 1674905 · Chief Financial Officer · last filed 2024-03-13
Sonja Nelson is a Chief Financial Officer who has filed 19 SEC Form 4 insider transactions across 3 companies since 2018. The most recent filing, for MOTS, was dated Mar 13, 2024. Across all open-market trades the lifetime net is −$905.9K, making them a net seller over the disclosed history.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
NK price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
1301 EAST BROWARD BOULEVARD, 3RD FLOOR
FT. LAUDERDALE, FL 33301
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Motus GI Holdings, Inc. (MOTS) Delisted | Director | 336 | $0.00 | $0 | $0 | 4 | 2024-03-13 |
| Ambrx Biopharma, Inc. (AMAM) Delisted | Chief Financial Officer | 0 | $28.00 | $0 | -$125.5K | 6 | 2024-03-07 |
| ImmunityBio, Inc. (NK) Delisted | Chief Financial Officer | 15,410 | — | — | -$780.4K | 8 | 2021-01-13 |
Recent Filings
19 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-03-13 | Motus GI Holdings, Inc. (MOTS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-03-07 | Ambrx Biopharma, Inc. (AMAM) Delisted | Disp (D) | −22,936 | $0 | EDGAR |
| 2023-12-11 | Ambrx Biopharma, Inc. (AMAM) Delisted | Grant (A) | +50,000 | $0 | EDGAR |
| 2023-10-31 | Ambrx Biopharma, Inc. (AMAM) Delisted | Sell (S) | −12,778 | -$125.5K | EDGAR |
| 2023-10-27 | — | Notice (144) | −12,778 | -$125.5K | EDGAR |
| 2023-07-07 | Ambrx Biopharma, Inc. (AMAM) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-04-28 | Ambrx Biopharma, Inc. (AMAM) Delisted | Grant (A) | +1,000,000 | $0 | EDGAR |
| 2023-01-31 | Ambrx Biopharma, Inc. (AMAM) Delisted | Mixed | — | $0 | EDGAR |
| 2022-02-11 | Motus GI Holdings, Inc. (MOTS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-01-07 | Motus GI Holdings, Inc. (MOTS) Delisted | Grant (A) | +82,500 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.